Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [31] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [31] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [32] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [32] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for the reported period, with a gross loss of $1.7 million [34] - Revenue from AI solutions for Q3 2025 was $0.1 million, with a gross loss of $1.9 million, compared to revenue of $0.4 million and a gross loss of $1.6 million in the comparable period [34] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][16] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [8] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, increasing revenues, and accelerating its path to profitability [5] - The strategy includes reinforcing its position in the medical AI sector and deepening its foothold in the U.S. healthcare system [5] - The acquisition of VasoHealthcare IT is intended to enhance the company's AI infrastructure and customer service capabilities [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by strategic partnerships and the acquisition of VasoHealthcare IT [6][38] - The company anticipates reaching EBITDA break-even on a quarterly basis in 2026 for the AI business segment and in 2027 for the overall company [30][44] Other Important Information - The company is preparing to launch its next-generation Nano-X ARC X system at the RSNA annual meeting, which is expected to enhance market penetration [9] - The company is actively engaged in clinical trials to validate the effectiveness of its imaging solutions, particularly in lung cancer detection [20] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The revenue was generated from a combination of scans and OEM services, with several systems being installed and awaiting regulatory approvals [40] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The majority of agreements are expected to be MSES, with some CapEx sales anticipated [40] Question: Could you talk about how OpEx could look over the next four to six quarters? - Investment in deployment efforts, particularly sales and marketing expenses, is expected to increase, while R&D expenses may be tamed [42] Question: Could you talk about Vaso and the types of customers they currently have? - Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities for Nano-X [42] Question: Could you reiterate the break-even expectations for 2026 and 2027? - The AI business is expected to achieve quarterly break-even in 2026, while the ARC hardware business aims for break-even in 2027 [44][46]

Core Insights - Nanox Imaging Ltd. reported a net loss of $13.7 million for Q3 2025, slightly higher than the $13.6 million loss in Q3 2024, indicating a marginal increase in losses year-over-year [4] - The company achieved revenue of $3.4 million in Q3 2025, up from $3.0 million in the same period last year, driven by teleradiology services and sales of imaging systems and AI solutions [5] - Nanox is focused on advancing its technologies, expanding its market presence, and enhancing operational efficiency, with significant progress made in these areas during the quarter [3] Financial Performance - The gross loss for Q3 2025 was $2.9 million, with a gross loss margin of 84%, compared to a gross loss of $2.8 million and a margin of 93% in Q3 2024 [6] - Revenue from teleradiology services increased to $3.1 million in Q3 2025 from $2.6 million in Q3 2024, with gross profit from these services rising to $0.8 million, reflecting a gross profit margin of approximately 25% [7] - Revenue from AI solutions decreased to $142 thousand in Q3 2025 from $434 thousand in Q3 2024, with a gross loss of $1.9 million [10] Operational Highlights - The company acquired Vaso Healthcare IT to enhance its AI solutions business and entered multiple global collaborations to accelerate the commercialization of Nanox.ARC and AI solutions [3][8] - Clinical trials have expanded to include Cedars-Sinai in Los Angeles and Olympe Imagerie in Paris, supporting the use of Nanox solutions [8] - Nanox has made strides in the European market, establishing distribution partnerships with EXRAY and Althea France SARL [8] Guidance and Future Outlook - The company anticipates deploying over 100 clinical, demo, and commercial units worldwide by the end of 2025, assuming stable macroeconomic conditions [17] - For the year 2026, Nanox expects revenues to reach $35 million, indicating a positive growth trajectory [19] Liquidity and Capital Resources - As of September 30, 2025, Nanox had total cash and marketable securities of $55.5 million, down from $83.2 million at the end of 2024, with negative cash flow from operations of $30.4 million during the reported period [20] - The company had approximately 65.4 million shares outstanding as of September 30, 2025, an increase from 63.8 million shares at the end of 2024 [22]

Core Insights - Nanox Imaging Ltd is set to release its quarterly earnings on November 20, 2025, with Wall Street expecting an EPS of -$0.175 and revenue of approximately $3.5 million [1][6] - The company has announced an agreement to acquire VasoHealthcare IT Inc. to enhance the rollout of its AI solutions in U.S. healthcare facilities [2][6] - Despite facing financial challenges, including a negative P/E ratio of -3.49, Nanox maintains a strong liquidity position with a current ratio of 4.19 [3][5][6] Financial Metrics - The price-to-sales ratio stands at 16.35, indicating high investor expectations for future growth despite current earnings difficulties [3] - The enterprise value to sales ratio is 12.82, while the enterprise value to operating cash flow ratio is -3.98, reflecting negative operating cash flow [4] - The company has a low debt-to-equity ratio of 0.05, suggesting minimal reliance on debt financing [5]

Core Viewpoint - Nanox Imaging Ltd has announced the acquisition of VasoHealthcare IT Inc to enhance the deployment of its AI solutions in U.S. healthcare facilities, with the transaction expected to be completed within weeks [1][2]. Company Overview - Nanox is focused on transforming healthcare through affordable medical imaging technologies that leverage advanced AI and proprietary digital X-ray sources [8]. - Vaso Corporation operates in diversified sectors, including healthcare technology and medical devices, with VHC IT being a key player in healthcare information technology [10]. Acquisition Details - The acquisition will involve a total consideration of up to $800,000, which includes a $200,000 cash payment at closing and up to $600,000 in performance-based earnout payments over two years, contingent on revenue retention from existing customers [5]. - VHC IT specializes in healthcare IT implementation, providing services such as systems integration, workflow optimization, and user training, which will be integrated with Nanox's AI solutions [3][4]. Strategic Implications - The integration of VHC IT's operational infrastructure with Nanox.AI's FDA-cleared solutions is expected to accelerate the deployment and adoption of AI technologies in medical imaging, enhancing the customer experience [4][6]. - The acquisition is anticipated to support Nanox's commercial expansion in the U.S. by leveraging VHC IT's expertise and established customer relationships [4][6].

Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration with Olympe Imagerie, a Paris-based group of independent radiologists, to deploy the Nanox.ARC and expand its clinical research evidence generation program in France. The Nanox.ARC system ...

Core Insights - Nanox Imaging Ltd will showcase its Nanox.ARC X multi-source digital tomosynthesis system and AI solutions at the RSNA 2025 Annual Meeting from November 30 to December 4, 2025 [1][2] Product Overview - The Nanox.ARC X system, which received FDA 510(k) clearance in April 2025, enables advanced 3D imaging at lower costs and radiation doses compared to CT scans, applicable for various medical indications [2][4] - Live demonstrations of the Nanox.ARC X will occur every 30 minutes at RSNA booth 3914, along with clinical data presentations supporting digital tomosynthesis [3][6] AI Innovations - Nanox is developing a pulmonary nodule AI solution as part of the Nanox.ARC X, along with two standalone AI innovations for measuring aortic valve calcification and body composition [3][4] - The company aims to leverage AI to enhance routine medical imaging efficiency and improve early detection of chronic conditions [9] Event Details - Presentations at RSNA include a focus on AI and digital tomosynthesis in pulmonary nodule detection and applications in the musculoskeletal system [5][6] - A cocktail event discussing the future of radiology and AI will be hosted by Dr. Lawrence Tanenbaum on December 1, 2025 [6][7] Company Vision - Nanox's vision is to expand its technology's reach beyond hospital settings, providing a comprehensive solution from scan to diagnosis, enhancing health outcomes through early detection and treatment [9]

Core Insights - Nanox Imaging Ltd will report its financial results for Q3 2025 on November 20, 2025, before market open [1] - The conference call to discuss these results will be hosted by CEO Erez Meltzer and CFO Ran Daniel at 8:30 a.m. ET [1] Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies utilizing advanced AI and proprietary digital X-ray sources [3] - The company's vision includes expanding its technology's reach beyond hospitals, providing a comprehensive solution from scan to diagnosis, and leveraging AI for improved diagnostic accuracy [4] Product Ecosystem - Nanox.ARC is a multi-source digital tomosynthesis system designed to be cost-effective and user-friendly [4] - Nanox.AI LTD offers an AI-based suite of algorithms that enhance routine CT imaging readings to detect early signs of chronic diseases [4] - Nanox.CLOUD is a cloud-based platform for managing data from Nanox devices, providing tools for in-depth imaging analysis [4] - Nanox.MARKETPLACE is a decentralized marketplace that offers remote access to radiology and cardiology experts, along with a teleradiology services platform [4]

Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with EXRAY, a leading Czech radiography supplier, to introduce its advanced imaging solutions in the Czech Republic [1][4] - The Nanox.ARC, a multi-source digital tomosynthesis system, is designed to provide enhanced diagnostic capabilities at a lower cost compared to traditional systems and has received CE Mark certification for commercialization in the EU [2][4] - EXRAY holds over 50% market penetration in the Czech Republic, with installations in more than half of the country's 200 healthcare facilities, making it a strategic partner for Nanox [3][4] Company Overview - Nanox focuses on transitioning to preventive healthcare through affordable medical imaging technologies, leveraging advanced AI and proprietary digital X-ray sources [5] - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI LTD, Nanox.CLOUD, and Nanox.MARKETPLACE, aimed at improving early detection and treatment of diseases [6] Strategic Importance - The partnership with EXRAY is seen as a significant milestone in Nanox's European expansion, utilizing EXRAY's established relationships with healthcare providers to enhance access to imaging services [4] - EXRAY's CEO emphasized the potential for improved diagnostic capabilities and patient outcomes through this collaboration [4]

Core Insights - Nanox Imaging Ltd has announced a collaboration with Monarch Medical Management and Billing LLC to deploy advanced imaging solutions across various healthcare segments, including workers' compensation, nursing homes, and outpatient clinics [1][2][4] Group 1: Collaboration Details - The collaboration aims to establish a comprehensive imaging network by deploying Nanox's technology across Monarch's associated healthcare facilities, with over a dozen initial sites identified for a proof-of-concept phase [2] - Nanox's advanced imaging services will be accessible to patients in multiple care settings, including the Nanox.ARC system, AI-powered software for analyzing CT scans, and teleradiology services [3][4] Group 2: Strategic Goals - The collaboration addresses critical imaging access challenges by providing faster access to high-quality imaging services, which can accelerate accurate diagnosis and treatment decisions for patients [4] - Nanox's vision includes expanding its technology reach beyond hospital settings, aiming for a seamless end-to-end solution from scan to diagnosis, leveraging AI for improved efficiency in medical imaging [6] Group 3: Company Background - Nanox is focused on transitioning the world to preventive healthcare through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [5] - The Nanox ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at enhancing early detection and treatment to improve health outcomes globally [6]

Group 1 - Nano-X Imaging Ltd. has faced challenges recently, with shares closing down 5.4% on August 12th following the announcement of second-quarter financial results [1] - The company is experiencing difficulties that have negatively impacted shareholder value [1] Group 2 - Crude Value Insights provides an investment service focused on oil and natural gas, emphasizing cash flow and companies that generate it [1] - The service aims to identify value and growth prospects within the sector [1]